SEC Form 4 · accession 0001144204-19-003609
NORTHWEST BIOTHERAPEUTICS INC · NWBO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Linda F Powers
Officer — President and CEO · Director · 10% Owner
Period of report
Dec 27, 2018
Accepted (ET)
Jan 29, 2019 · 9:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001072379
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Restricted Common Stock, par value $0.001F1 | Dec 28, 2018 | S | 804,146 | $0.17 | D | 0 | I | Sale by Toucan Capital Fund III, LP. |
| Restricted Common Stock, par value $0.001F2 | Dec 27, 2018 | S | 3,558,639 | $0.17 | D | 29,411,760 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Class D-2 Warrants | $0.30 | Dec 28, 2018 | S | 402,073 | D | May 4, 2018 | May 4, 2023 | Common Stock, par value $0.001 | 402,073 | 0 | I |
| Class D-2 Warrants | $0.30 | Dec 27, 2018 | S | 1,779,320 | D | May 4, 2018 | May 4, 2023 | Common Stock, par value $0.001 | 1,779,320 | 0 | D |
Explanation of responses
- F1Toucan Capital Fund III, LP sold the 804,146 restricted shares of common stock that it owned, in preparation for the required dissolution due to the Toucan Fund reaching the end of its contractual term. The reporting person has management control as well as a partnership interest in the Toucan Fund.
- F2The reporting party sold shares of restricted common stock.